Healthcare Revolution Series: Redefining glaucoma treatment – discussion with SpyGlass Pharma

Research evidence excerpt

Healthcare Revolution Series: Redefining glaucoma treatment – discussion with SpyGlass Pharma

Accessible version

Healthcare Revolution Series

Redefining glaucoma treatment –

discussion with SpyGlass Pharma

Industry Overview

Key takeaways from meeting with management 10 June 2026

We hosted SpyGlass Pharma’s (not covered) management team: Patrick Mooney, CEO; Equity

Dr. Jean-Frédéric Viret, CFO; and James Dennewill, COO. Below are the key takeaways Europe

from our discussion. As relates to our coverage, while we don’t see any immediate risk Health Care

for Alcon, SpyGlass could add competition in the glaucoma treatment landscape in the Julien Ouaddour >>

mid-term, depending on clinical studies and adoption. Research Analyst

BofASE (France)

BIM-IOL: Drop-free glaucoma treatment +33julien.ouaddour@bofa.com1 8770 0614

SpyGlass is positioning BIM-IOL as a sustained drug-delivery IOL for glaucoma patients James Nin >>

undergoing cataract surgery as glaucoma drops are effective, but adherence is poor. ResearchBofASE (France)Analyst

BIM-IOL addresses this by embedding bimatoprost delivery into the lens for up to three james.nin@bofa.com

years, potentially reducing or eliminating the need for daily topical therapy. Management Anna Ractliffe >>

Research Analyst

sees a sizeable opportunity, with around 20% of cataract patients also having glaucoma, MLI (UK)

implying c.1m eligible procedures in the US and c.5.4m globally. SpyGlass frames the +44 020 7995 2591

anna.ractliffe@bofa.com

addressable market at c.$13bn, based on c.$14k per-unit economics, with potential

commercialization around 2029.

505 (b) (2) = FDA drug approval

Adoption hinges on workflow and reimbursement process that allows use of existing

The drug component is expected to follow a 505(b)(2) NDA pathway, while data